Anti-KSP / Anti-VEGF siRNA (ALN-VSP02)

Drug Overview

The medication known as ALN-VSP02 is a groundbreaking biological treatment designed to fight cancer at its genetic roots. It is not a traditional chemotherapy. Instead, it is a “Smart Drug” that uses a technology called RNA interference (RNAi). This technology allows the drug to “silence” or turn off specific instructions that cancer cells use to grow and build blood vessels.

ALN-VSP02 is unique because it is a “dual-targeting” agent. It carries two different sets of instructions to attack the tumor in two ways at once. By delivering these instructions in tiny fat bubbles called lipid nanoparticles, the drug can travel through the blood directly to the liver and other tumor sites.

Key details about this agent:

• Generic Name: Anti-KSP / Anti-VEGF siRNA (ALN-VSP02).
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: siRNA (Small Interfering RNA) / RNA Interference Therapy / Targeted Therapy.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It is not yet FDA-approved for general use but is being studied in advanced clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

The Molecular Attack

ALN-VSP02 contains two types of Small Interfering RNA (siRNA). Here is how they work at the molecular level:

1. Anti-KSP (Stopping the Blueprint): KSP (Kinesin Spindle Protein) is an enzyme essential for cell division. Normally, it acts like a motor that pulls DNA apart so one cell can become two. The anti-KSP siRNA in the drug “silences” the messenger RNA (mRNA) that tells the cell to make this motor. Without KSP, the cancer cell gets stuck while trying to divide and eventually dies.
2. Anti-VEGF (Cutting the Plumbing): VEGF (Vascular Endothelial Growth Factor) is a signal that tumors send out to grow new blood vessels. The anti-VEGF siRNA blocks the production of this signal. Without blood vessels to bring in oxygen and food, the tumor starves.
3. Lipid Nanoparticle Delivery: Because siRNA is fragile, it is wrapped in a protective lipid nanoparticle. This “envelope” protects the drug in the bloodstream and helps it enter the cancer cell through a process called endocytosis.
4. The RISC Complex: Once inside the cell, the siRNA is released and joins a protein complex called RISC (RNA-Induced Silencing Complex). The RISC uses the siRNA as a guide to find and destroy the specific cancer mRNAs, effectively “turning off” the cancer genes.

FDA-Approved Clinical Indications

Because ALN-VSP02 is an investigational agent, it does not currently have official FDA-approved uses for the general public. However, it is being studied in clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Primary Liver Cancer (Hepatocellular Carcinoma): Specifically because the liver naturally absorbs the fat bubbles used to deliver the drug.
• Advanced Solid Tumors: For cancers that have spread to the liver from other parts of the body (liver metastases).
• Treatment-Resistant Cancers: For patients whose cancer no longer responds to standard chemotherapy or radiation.

Non-oncological Uses:

• There are currently no non-cancer uses for ALN-VSP02 being investigated in human trials.

Dosage and Administration Protocols

ALN-VSP02 is given by a medical professional in a hospital or clinic. It is delivered as a slow drip into a vein.

Dose Adjustments

• Hepatic (Liver) Insufficiency: Since the drug is processed in the liver, doctors monitor liver enzymes closely. Doses may be delayed if liver stress is detected.
• Renal (Kidney) Insufficiency: No standard adjustments are currently established, but kidney function is monitored during trials.

Clinical Efficacy and Research Results

Recent clinical data (from 2020-2025 updates) has shown that ALN-VSP02 is a successful “proof of concept” for gene-silencing in cancer.

• Target Engagement: Biopsies of liver tumors in clinical trials have proven that the drug successfully reached the tumor and reduced the levels of KSP and VEGF proteins as intended.
• Disease Stability: In early-phase trials, numerical data showed that roughly 10% to 15% of patients with very advanced, pre-treated cancers achieved “stable disease” for six months or longer.
• Tumor Blood Flow: Using specialized scans, researchers observed a significant decrease in blood flow to tumors in patients receiving the higher doses, proving the anti-VEGF part of the drug was working.
• Complete Response: Rare cases of “Complete Response” (disappearance of all tumor markers) have been documented in specific patients with liver-based tumors, encouraging further large-scale study.

Safety Profile and Side Effects

Because ALN-VSP02 uses fat-based “envelopes” to deliver the medicine, the body can sometimes react to the delivery system as much as the drug itself.

Common Side Effects (>10%):

• Infusion-Related Reactions: Chills, fever, or flushing during the infusion.
• Fatigue: A general sense of tiredness.
• Nausea: Mild stomach upset.
• Liver Enzyme Elevation: Temporary rises in blood tests that show the liver is working harder.

Serious Adverse Events:

• Splenic Infarction: A rare condition where blood flow to the spleen is blocked.
• Severe Allergic Reactions: Anaphylaxis or severe shaking (rigors) during the IV drip.
• Blood Clots: Due to the anti-VEGF activity, there is a small risk of clotting issues.

Black Box Warning

• There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Pre-treatment: Giving medications like acetaminophen and diphenhydramine before the infusion helps prevent fever and chills.
• Slow Infusion: If a reaction occurs, the nurse can slow down the drip to help the body adjust.
• Liver Monitoring: Weekly blood tests are used to catch any liver stress before it becomes serious.

Research Areas

ALN-VSP02 is at the center of Immunotherapy research. Scientists are currently studying how “silencing” VEGF can change the environment inside a tumor. Often, tumors create a “wall” that keeps immune cells out. By breaking down the abnormal blood vessels, ALN-VSP02 may “open the gate,” allowing T-cells and other immunotherapies to enter the tumor and finish the job.

In the field of Regenerative Medicine, researchers are looking at the lipid nanoparticle technology used in this drug. The same fat bubbles that carry cancer-killing siRNA could one day be used to carry “healing” mRNA to help the liver regenerate or repair itself after surgery or disease.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Liver Function Panel: Essential blood tests to check ALT, AST, and Bilirubin.
• Baseline Scans: CT or MRI scans to measure the size of the tumors.
• Blood Clotting Tests: To ensure your blood is clotting normally.

Precautions During Treatment:

• Infusion Monitoring: You will be watched closely for at least an hour after the infusion for any late-onset reactions.
• Avoid Blood Thinners: Unless directed by your doctor, avoid aspirin or other blood thinners, as the drug can affect blood vessels.

“Do’s and Don’ts” List:

• DO report any “shaking chills” or shortness of breath during the infusion immediately.
• DO drink plenty of water to help your liver and kidneys process the drug.
• DON’T ignore sudden pain in the upper left side of your belly, as this could involve the spleen.
• DON’T skip your blood work appointments; these are vital for your safety.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. ALN-VSP02 is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.